Abstract
Introduction: Non-Small Cell Lung Cancer (NSCLC) is an aggressive malignancy with poor overall survival that accounts for up to 85% of lung cancer diagnoses. The use of immunotherapy in the form of checkpoint inhibition, to enhance the immune system’s ability to attack malignant cells, has been a promising addition to treatment options in advanced NSCLC.
Results: Such therapeutic agents aimed at the Programmed Death 1 (PD-1) receptor or Programmed Death Ligand 1 (PD-L1) have revealed promising results against many types of cancer including NSCLC. Examples of these agents include nivolumab, pembrolizumab, BMS-936559, atezolizumab, and MEDI4736, of which the first two are approved by US FDA in the second line treatment of advanced NSCLC.
Discussion: Impressive improvements in objective responses from PD-1 blockade were found in both first line therapy as well as treatment after progression on platinum based therapy. In addition, the safety profile is favorable with significantly lower grade 3-4 adverse events compared to standard of care. The optimal selection criteria and factors that show an increased response to therapy are still being determined.
Keywords: Immune Checkpoint Inhibitors, Non-Small-Cell Lung Cancer.
Reviews on Recent Clinical Trials
Title:Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer
Volume: 11 Issue: 4
Author(s): Anshu Giri, Simrit S. Walia and Ajeet Gajra
Affiliation:
Keywords: Immune Checkpoint Inhibitors, Non-Small-Cell Lung Cancer.
Abstract: Introduction: Non-Small Cell Lung Cancer (NSCLC) is an aggressive malignancy with poor overall survival that accounts for up to 85% of lung cancer diagnoses. The use of immunotherapy in the form of checkpoint inhibition, to enhance the immune system’s ability to attack malignant cells, has been a promising addition to treatment options in advanced NSCLC.
Results: Such therapeutic agents aimed at the Programmed Death 1 (PD-1) receptor or Programmed Death Ligand 1 (PD-L1) have revealed promising results against many types of cancer including NSCLC. Examples of these agents include nivolumab, pembrolizumab, BMS-936559, atezolizumab, and MEDI4736, of which the first two are approved by US FDA in the second line treatment of advanced NSCLC.
Discussion: Impressive improvements in objective responses from PD-1 blockade were found in both first line therapy as well as treatment after progression on platinum based therapy. In addition, the safety profile is favorable with significantly lower grade 3-4 adverse events compared to standard of care. The optimal selection criteria and factors that show an increased response to therapy are still being determined.
Export Options
About this article
Cite this article as:
Giri Anshu, Walia S. Simrit and Gajra Ajeet, Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer, Reviews on Recent Clinical Trials 2016; 11 (4) . https://dx.doi.org/10.2174/1574887111666160724181330
DOI https://dx.doi.org/10.2174/1574887111666160724181330 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
miR-1247 is Correlated with Prognosis of Pancreatic Cancer and Inhibits Cell Proliferation by Targeting Neuropilins
Current Molecular Medicine Phytochemical and Biological Activities of an Anticancer Plant Medicine: Brucea javanica
Anti-Cancer Agents in Medicinal Chemistry Distribution, Bioactivities and Therapeutical Potentials of Pentagalloylglucopyranose
Current Bioactive Compounds SUMOylation Modulates CFTR Biogenesis: Is the Pathway Druggable?
Current Drug Targets Hematopoietic Stem Cells: Transcriptional Regulation, Ex Vivo Expansion and Clinical Application
Current Molecular Medicine Antisense Treatment in Human Prostate Cancer and Melanoma
Current Cancer Drug Targets Can the Use of HIV-1 Derived Gene Transfer Vectors for Clinical Application be Justified?
Current Gene Therapy Stem Cell Therapy in Chronic Obstructive Pulmonary Disease. Seeking the Prometheus Effect
Current Drug Targets Potential Utilization of Bystander / Abscopal-Mediated Signal Transduction Events in the Treatment of Solid Tumors
Current Signal Transduction Therapy Adenovirus-Based Cancer Gene Therapy
Current Gene Therapy Cruciferous Plants: Phytochemical Toxicity Versus Cancer Chemoprotection
Mini-Reviews in Medicinal Chemistry Application of Molecular Imaging Technologies in Antitumor Drug Development and Therapy
Current Pharmaceutical Design Design, Synthesis and Antiplasmodial Evaluation of Sulfoximine-triazole Hybrids as Potential Antimalarial Prototypes
Medicinal Chemistry Imatinib and Its Successors – How Modern Chemistry has Changed Drug Development
Current Pharmaceutical Design Recent Applications of Phosphoproteomics
Current Proteomics Synthesis and Antifungal Activity Evaluation of New 1,2,4-Triazole Derivatives Bearing Salicylidene Hydrazide Moiety
Letters in Drug Design & Discovery Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era
Current Cancer Drug Targets Challenges in the Discovery of Novel Therapeutic Agents in Cancer
Current Drug Metabolism Meet Our Editorial Board Member:
Recent Patents on Regenerative Medicine Targeting p73 - a Potential Approach in Cancer Treatment
Current Pharmaceutical Design